Correlation of Serum Hepatitis C Viral Load and Immunobiochemical biomarkers in Combined Therapy Treated Patients | ||||
| International Journal of Theoretical and Applied Research | ||||
| Article 4, Volume 2, Issue 2, December 2023, Page 183-201 PDF (2.04 MB) | ||||
| Document Type: Original Article | ||||
| DOI: 10.21608/ijtar.2023.197680.1038 | ||||
 View on SCiNiTO | ||||
| Authors | ||||
Fathia Ahmed Ibrahim   1; maha ghazi soliman2; Hanaa Abdelfattah Elsaied3
| ||||
| 1Laboratory Section, Ministry of Health, Giza, Egypt | ||||
| 2zoology-entomology, faculty of science, al-azhar university, Cairo, Egypt | ||||
| 3medical microbilogy ,National organization for drug control and research, cairo, egypt | ||||
| Abstract | ||||
| Hepatitis C virus (HCV) infection is a major global disease that frequently causes chronicity and has the potential to cause liver failure and it is widespread in Egypt. Direct acting antivirals (DAAs) are a revolution in HCV treatment. Sofosbuvir (Sovaldi) is pan genotypic while, Daclatasvir has a wide range of HCV genotypes A correlation analysis is the study of how variables are correlated to each other. The current study aimed to explore the potential correlation between quantitatively detected virus C load using quantitative reverse‐transcription polymerase chain reaction (qRT‐PCR) assay and some immunological, biochemical and hematological biomarkers. Results from 600 HCV-positive people ranged between 25 and 55 years old were analyzed using the Prism, a computer program (Graph Pad software. Version 5, San Diego, CA), and concluded that, there were a significant relation between HCV viral load and immuno-biological biomarkers. Also, the present study referred to the efficacy of Sofosbuvir/Daclatasvir combined therapy where 100% Sustained Virological Response (SVR) in all patients. | ||||
| Keywords | ||||
| HCV; immunological; biochemical; hematological | ||||
|
Statistics Article View: 61 PDF Download: 90 |
||||
